Evidence map›Paper›PMID 33665482›Full record

ArticleAdvances in radiation oncology

Outcomes After Stereotactic Body Radiation Therapy as a Bridging Modality to Liver Transplantation for Hepatocellular Carcinoma.

Rashi Garg, Kimberly Foley, Babak Movahedi, Mark J Masciocchi, Jacob R Bledsoe, Linda Ding, Paul Rava, Thomas J Fitzgerald, Shirin Sioshansi

Abstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. SBRT for bridging and downstaging HCC before transplant.JHEP reports : innovation in hepatology · 2025
    Article
  3. Review
  4. Multi-contrast 4DMR via MR multitasking: Early clinical experience and implication for liver stereotactic body radiation therapy.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2025
    Article
  5. No disease left behind.Oncotarget · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rashi GargDepartment of Radiation Oncology, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts.
Kimberly FoleyDepartment of Transplant Surgery, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.
Babak MovahediDepartment of Transplant Surgery, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.
Mark J MasciocchiDepartment of Radiology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.
Jacob R BledsoeDepartment of Pathology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.
Linda DingDepartment of Radiation Oncology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.
Paul RavaDepartment of Radiation Oncology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.
Thomas J FitzgeraldDepartment of Radiation Oncology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.
Shirin SioshansiDepartment of Radiation Oncology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFor patients with hepatocellular carcinoma awaiting liver transplantation (LT), stereotactic body radiation therapy (SBRT) has emerged as a bridging treatment to ensure patients maintain priority status and eligibility per Milan criteria. In this study, we aimed to determine the efficacy and safety of SBRT in such situations. METHODS AND MATERIALS: A retrospective analysis was conducted of the outcomes of 27 patients treated with SBRT who were listed for LT at 1 institution. Among these, 20 patients with 26 tumors went on to LT and were the focus of this study. Operative reports and postoperative charts were evaluated for potential radiation-related complications. The explant pathology findings were correlated with equivalent dose in 2 Gy fractions and tumor size.

resultsMedian pretreatment tumor size was 3.05 cm. Median total dose of radiation was 50 Gy delivered in 5 fractions. Pathologic complete response (pCR) was achieved in 16 tumors (62%). Median interval from end of SBRT to transplant was 287 days. Of the 21 tumors imaged before transplant, 16 or 76% demonstrated a clinical complete response based on modified Response Evaluation Criteria in Solid Tumors criteria. There was no significant correlation between pCR rate and increasing tumor size (odds ratio [OR], 0.95; 95% confidence interval, 0.595-1.53) or pCR rate and equivalent dose in 2 Gy fractions (OR, 1.03; 95% confidence interval, 0.984-1.07.) No patients experienced radiation-related operative or postoperative complications. Of the 27 patients who were listed for transplant, the dropout rate was 22%. Two of the 5 patients with Child-Pugh score 10 died of liver failure.

conclusionsThese data demonstrate that SBRT as a bridging modality is a feasible option, with a pCR rate comparable to that of other bridging modalities and no additional radiation-related operative or postoperative complications. There was no dose dependence nor size dependence for pCR rate, which may indicate that for the tumor sizes in this study, the radiation doses delivered were sufficiently high.

Identifiers

PMID33665482
PMCPMC7897771

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.